Serum miR‐146a level is a potential biomarker in predicting the outcome of diffuse large B‐cell lymphoma

Abstract Background Diffuse large B‐cell lymphoma (DLBCL) is the most common subtype of non‐Hodgkin lymphoma with heterogenicity in clinical manifestation and prognosis. Some microRNAs can influence the development of tumors and may be related to the response of therapy or prognosis. This study aims to explore the role of serum miR‐146a in predicting the prognosis of DLBCL. Methods A total of 72 de novo DLBCL patients received 6 cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or rituximab combined CHOP (R‐CHOP) regimen, and their serum samples were collected before treatment and after 4 cycles of chemotherapy. Results The results show that a high level of miR‐146a is significantly associated with a good outcome in baseline and is more obvious in post‐chemotherapy. In addition, a high level of miR‐146a was associated with better progression‐free survival and overall survival in patients treated with R‐CHOP but has not been related to a superior outcome in patients treated with CHOP. Rituximab may improve the efficacy of therapy, especially in patients with high miR‐146a levels. The level of miR‐146a decreased in more patients after chemotherapy, and it seems patients with a decreased expression of miR‐146a after chemotherapy tended a better outcome, but it is not statistically significant. Conclusion Our results suggest that the level of serum miR‐146a can serve as a potential prognostic biomarker for DLBCL patients.